Cover Image
市場調查報告書

遺傳基因疾病相關的合作條件、契約

Global Genetic disorders Partnering 2010-2016: Deal trends, players and financials

出版商 Current Partnering, a division of Wildwood Ventures Limited 商品編碼 263658
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
Back to Top
遺傳基因疾病相關的合作條件、契約 Global Genetic disorders Partnering 2010-2016: Deal trends, players and financials
出版日期: 2016年09月01日 內容資訊: 英文
簡介

本報告提供全球遺傳基因疾病市場上企業合作契約的締結趨勢與內容(合作條件)相關分析、近幾年的合作契約/交易的形成情形與特徵(各類型、開發階段、適應症)、平均交易條件、代表性契約的概要、大醫藥品企業趨勢、近幾年的合作交易一覽與其明細等資訊彙整,為您概述為以下內容。

摘要整理

第1章 簡介

第2章 遺傳基因疾病相關的交易形成趨勢

  • 簡介
  • 近幾年遺傳基因疾病相關的合作趨勢
  • 大醫藥品企業的遺傳基因疾病相關的契約締結活動
  • 在遺傳基因疾病領域不活躍的大型製藥企業
  • 遺傳基因疾病相關的合作:各交易類型
  • 遺傳基因疾病相關的合作:各產業
  • 遺傳基因疾病相關的合作:各開發階段
  • 遺傳基因疾病相關的合作:各技術種類
  • 遺傳基因疾病相關的合作:各適應症
  • 遺傳基因疾病相關合作的平均契約條件
    • 交易總額
    • 預付款金
    • 階段性付款
    • 權利金費率

第3章 代表性遺傳基因疾病相關的契約

  • 簡介
  • 有代表性的契約:各金額
  • 大型製藥企業參加的代表性契約

第4章 大醫藥品企業的遺傳基因疾病相關的合作契約

  • 簡介
  • 與大醫藥品企業合作契約的有效利用方法
  • 大醫藥品企業簡介(共31家)

第5章 遺傳基因疾病相關的合作契約一覽

  • 簡介
  • 各交易類型
  • 各開發階段
  • 各技術種類

第6章 各治療標靶的契約締結趨勢

  • 簡介
  • 各治療標靶的契約動向
    • 遺傳基因疾病
    • 亨丁頓舞蹈症
    • 唐氏症
    • 囊腫纖維化
    • 鐮狀細胞
    • 神經纖維瘤
    • 脆弱X染色體症候群
    • 遺傳性血管水腫
    • 其他

第7章 合作資源中心

  • 線上合作
  • 合作趨勢
  • 相關調查

附錄

  • 附錄1 遺傳基因疾病相關的契約的一覽:各企業(ABC順序)
  • 附錄2 遺傳基因疾病相關的契約的一覽:各契約的類型
  • 附錄3 遺傳基因疾病相關的契約的一覽:各開發階段
  • 附錄4 遺傳基因疾病相關的契約的一覽:各技術種類
  • 附錄5 契約的種類定義

關於Wildwood Ventures

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: CP2218

‘Global Genetic disorders Partnering 2010-2016: Deal trends, players and financials’ report provides comprehensive understanding and unprecedented access to the genetic disorders partnering deals and agreements entered into by the worlds leading healthcare companies

‘Global Genetic Disorders Partnering 2010 to 2016’ provides the full collection of Genetic Disorders disease deals signed between the world's pharmaceutical and biotechnology companies since 2010.

  • Trends in Genetic Disorders partnering deals
  • Financial deal terms for headline, upfront and royalty by stage of development
  • Genetic Disorders partnering agreement structure
  • Genetic Disorders partnering contract documents
  • Top Genetic Disorders deals by value
  • Most active Genetic Disorders dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Genetic Disorders disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Genetic Disorders deals.

The report presents financial deal terms values for Genetic Disorders deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Genetic Disorders dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Genetic Disorders dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Genetic Disorders deals since 2010. Deals are listed by headline value. The chapter includes the top 25 most active Genetic Disorders dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Genetic Disorders deals since 2010 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Genetic Disorders partnering deals by specific Genetic Disorders target announced since 2010. The chapter is organized by specific Genetic Disorders therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Genetic Disorders partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Genetic Disorders partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Genetic Disorders technologies and products.

Report scope

‘Global Genetic Disorders Partnering 2010 to 2016’ is intended to provide the reader with an in-depth understanding and access to Genetic Disorders trends and structure of deals entered into by leading companies worldwide.

‘Global Genetic Disorders Partnering 2010 to 2016’ includes:

  • Trends in Genetic Disorders dealmaking in the biopharma industry since 2010
  • Analysis of Genetic Disorders deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to hundreds of Genetic Disorders deal contract documents
  • Comprehensive access to over 3500 Genetic Disorders deal records
  • The leading Genetic Disorders deals by value since 2010
  • Most active Genetic Disorders dealmakers since 2010

The report includes deals for the following indications: Cystic Fibrosis (CF), Down syndrome, Fragile X Syndrome, Hereditary angioedema, Huntington's disease, Rare genetic disorders, Neurofibromatosis, Sickle cell disease, plus other genetic indications.

In ‘Global Genetic Disorders Partnering 2010 to 2016’, available deals and contracts are listed by:

  • Headline value
  • Upfront payment value
  • Royalty rate value
  • Stage of development at signing
  • Deal component type
  • Technology type
  • Specific therapy indication

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The ‘Global Genetic Disorders Partnering 2010-2016’ report provides comprehensive access to available deals and contract documents for over 400 genetic disorders deals. Analyzing actual contract agreements allows assessment of the following:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are the sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Benefits

‘Global Genetic Disorders Partnering 2010 to 2016’ provides the reader with the following key benefits:

  • In-depth understanding of Genetic Disorders deal trends since 2010
  • Access Genetic Disorders deal headline, upfront, milestone and royalty data
  • Research hundreds of actual contracts between Genetic Disorders partner companies
  • Comprehensive access to over 750 links to actual Genetic Disorders deals entered into by the world's biopharma companies
  • Indepth review of Genetic Disorders deals entered into by the top 25 most active dealmakers
  • Benchmark the key deal terms companies have agreed in previous deals
  • Identify key terms under which companies partner Genetic Disorders opportunities
  • Uncover companies actively partnering Genetic Disorders opportunities

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Genetic Disorders dealmaking

  • 2.1. Introduction
  • 2.2. Genetic Disorders partnering over the years
  • 2.3. Genetic Disorders partnering by deal type
  • 2.4. Genetic Disorders partnering by industry sector
  • 2.5. Genetic Disorders partnering by stage of development
  • 2.6. Genetic Disorders partnering by technology type
  • 2.7. Genetic Disorders partnering by therapeutic indication

Chapter 3 -Financial deal terms for Genetic Disorders partnering

  • 3.1. Introduction
  • 3.2. Disclosed financials terms for Genetic Disorders partnering
  • 3.3. Genetic Disorders partnering headline values
  • 3.4. Genetic Disorders deal upfront payments
  • 3.5. Genetic Disorders deal milestone payments
  • 3.6. Genetic Disorders royalty rates

Chapter 4 - Leading Genetic Disorders deals and dealmakers

  • 4.1. Introduction
  • 4.2. Most active in Genetic Disorders partnering
  • 4.3. List of most active dealmakers in Genetic Disorders
  • 4.4. Top Genetic Disorders deals by value

Chapter 5 - Genetic Disorders contract document directory

  • 5.1. Introduction
  • 5.2. Genetic Disorders partnering deals where contract document available

Chapter 6 - Genetic Disorders dealmaking by therapeutic target

  • 6.1. Introduction
  • 6.2. Deals by Genetic Disorders therapeutic target

Appendices

  • Appendix 1 - Directory of Genetic Disorders deals by company A-Z 2010 to 2016
  • Appendix 2 - Directory of Genetic Disorders deals by deal type 2010 to 2016
  • Appendix 3 - Directory of Genetic Disorders deals by stage of development 2010 to 2016
  • Appendix 4 - Directory of Genetic Disorders deals by technology type 2010 to 2016
  • Further reading on dealmaking
  • Deal type definitions

About Wildwood Ventures

  • Current Partnering
  • Current Agreements
  • Recent report titles from CurrentPartnering

Table of figures

  • Figure 1: Genetic Disorders partnering since 2010
  • Figure 2: Genetic Disorders partnering by deal type since 2010
  • Figure 3: Genetic Disorders partnering by industry sector since 2010
  • Figure 4: Genetic Disorders partnering by stage of development since 2010
  • Figure 5: Genetic Disorders partnering by technology type since 2010
  • Figure 6: Genetic Disorders partnering by indication since 2010
  • Figure 7: Genetic Disorders deals with a headline value
  • Figure 8: Genetic Disorders deals with upfront payment values
  • Figure 9: Genetic Disorders deals with milestone payment
  • Figure 10: Genetic Disorders deals with royalty rates
  • Figure 11: Active Genetic Disorders dealmaking activity- 2010 to 2016
  • Figure 12: Top Genetic Disorders deals by value since 2010
Back to Top